Your browser doesn't support javascript.
loading
Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade.
Gomez-Roca, Carlos; Cassier, Philippe; Zamarin, Dmitriy; Machiels, Jean-Pascal; Perez Gracia, Jose Luis; Stephen Hodi, F; Taus, Alvaro; Martinez Garcia, Maria; Boni, Valentina; Eder, Joseph P; Hafez, Navid; Sullivan, Ryan; Mcdermott, David; Champiat, Stephane; Aspeslagh, Sandrine; Terret, Catherine; Jegg, Anna-Maria; Jacob, Wolfgang; Cannarile, Michael A; Ries, Carola; Korski, Konstanty; Michielin, Francesca; Christen, Randolph; Babitzki, Galina; Watson, Carl; Meneses-Lorente, Georgina; Weisser, Martin; Rüttinger, Dominik; Delord, Jean-Pierre; Marabelle, Aurelien.
Afiliação
  • Gomez-Roca C; Department of Medical Oncology and Clinical Research Unit, Institut Claudius Regaud, Toulouse, France gomez-roca.carlos@iuct-oncopole.fr.
  • Cassier P; Department of Medicine, Centre Leon Berard, Lyon, France.
  • Zamarin D; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, New York, USA.
  • Machiels JP; Department of Medical Oncology, Cliniques Universitaires Saint-Luc, Bruxelles, Belgium.
  • Perez Gracia JL; Department of Oncology, Universidad de Navarra, Pamplona, UK.
  • Stephen Hodi F; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Taus A; Department of Medical Oncology, Hospital del Mar, Barcelona, Spain.
  • Martinez Garcia M; Department of Medical Oncology, Hospital del Mar, Barcelona, Spain.
  • Boni V; Medical Oncology, Hospital Universitario HM Sanchinarro, Madrid, Spain.
  • Eder JP; Department of Medical Oncology, Yale University Yale Cancer Center, New Haven, Connecticut, USA.
  • Hafez N; Department of Medical Oncology, Yale University Yale Cancer Center, New Haven, Connecticut, USA.
  • Sullivan R; Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA.
  • Mcdermott D; Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
  • Champiat S; Drug Development Department, Gustave Roussy Institute, Villejuif, France.
  • Aspeslagh S; Drug Development Department, Gustave Roussy Institute, Villejuif, France.
  • Terret C; Department of Medicine, Centre Leon Berard, Lyon, France.
  • Jegg AM; Roche Innovation Center Munich, Penzberg, Germany.
  • Jacob W; Roche Innovation Center Munich, Penzberg, Germany.
  • Cannarile MA; Roche Innovation Center Munich, Penzberg, Germany.
  • Ries C; Roche Innovation Center Munich, Penzberg, Germany.
  • Korski K; Roche Innovation Center Munich, Penzberg, Germany.
  • Michielin F; Roche Innovation Center Basel, Basel, Switzerland.
  • Christen R; Roche Innovation Center Basel, Basel, Switzerland.
  • Babitzki G; Roche Innovation Center Munich, Penzberg, Germany.
  • Watson C; A4P Ltd, Sandwich, UK.
  • Meneses-Lorente G; Roche Innovation Center Welwyn, Welwyn Garden City, UK.
  • Weisser M; Roche Innovation Center Munich, Penzberg, Germany.
  • Rüttinger D; Roche Innovation Center Munich, Penzberg, Germany.
  • Delord JP; Department of Medical Oncology and Clinical Research Unit, Institut Claudius Regaud, Toulouse, France.
  • Marabelle A; Drug Development Department, Gustave Roussy Institute, Villejuif, France.
J Immunother Cancer ; 10(5)2022 05.
Article em En | MEDLINE | ID: mdl-35577503
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Bexiga Urinária / Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares / Melanoma Limite: Humans Idioma: En Revista: J Immunother Cancer Ano de publicação: 2022 Tipo de documento: Article País de afiliação: França
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Bexiga Urinária / Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares / Melanoma Limite: Humans Idioma: En Revista: J Immunother Cancer Ano de publicação: 2022 Tipo de documento: Article País de afiliação: França